Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has launched over-the-counter (OTC) Fexofenadine HCI 180 mg and Pseudoephedrine HCI 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy’s OTC Fexofenadine HCI 180 mg and Pseudoephedrine HCI 240 mg Extended Release Tablets, USP is an over-the-counter oral antihistamine and nasal decongestant for the temporary relief of nasal and sinus congestion due to colds or allergies. It temporarily relieves sneezing; runny nose; itchy, watery eyes; and itchy nose or throat due to allergies. Allegra-D 24 HR had U.S. retail sales of approximately $45 million as of May 2022 according to IRI. Dr. Reddy’s OTC Fexofenadine HCI 180 mg and Pseudoephedrine HCI 240 mg Extended Release Tablets, USP will be available in 5-count, 10-count, and 15-count pack sizes.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.